Although considered a single class, fecal immunochemical tests (FITs) vary in their ability to detect advanced colorectal neoplasia (ACN) and should not be considered interchangeable, new research ...

A new study published in the Journal of American Medical Association showed that despite partial participant adherence, it ...

Multitarget stool-based tests are showing promise for colorectal cancer (CRC) screening in average-risk individuals and could edge out the current standard fecal immunochemical test (FIT). These new ...

Stool-based testing has poor sensitivity and low negative predictive value for colorectal cancer screening in patients with cystic fibrosis.

Commercial FITs can match NG-MSDT diagnostic results for CRC by lowering the positivity threshold, enhancing sensitivity while maintaining specificity. FITs are accessible, noninvasive CRC screening ...

A brief research report compared screening costs per early-detected colorectal cancer (CRC) case among fecal immunochemical tests (FIT), multitarget stool DNA tests (MSDT) and next-generation MSDTs (N ...

Lowering the fecal immunochemical test (FIT) positive threshold yields levels of sensitivity and specificity that are comparable to those reported for multitarget stool RNA (mt-sRNA) testing without ...

In DID analysis, the rate of incidence was reduced by 0.34 cases per person-years in the screening group as compared with the historical FIT screening group (rate ratio [RR], 0.08 [95% CI, 0.07 to ...

More than 10% of fecal immunochemical test (FIT)–based colorectal cancer screening could not be processed due to unsatisfactory samples. Colorectal cancer (CRC) screening using the fecal ...

The U.S. Preventive Services Task Force recommends colorectal cancer screening for all adults starting at age 45. After age 75, the task force recommends talking with your health care team to decide ...

The FIT test analyzed in the study has patients poke a stool sample with a plastic stick and return it to a lab, which checks ...